Evidence map›Paper›PMID 38137701›Full record

ReviewJournal of clinical medicine2023

Antithrombotic Management for Transcatheter Aortic Valve Implantation.

Lina Ya'Qoub, Jelena Arnautovic, Musa Sharkawi, Mirvat AlAasnag, Hani Jneid, Islam Y Elgendy

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Cerebrovascular Events in Aortic Stenosis: From Native Valve Disease to TAVR-Specific Risk and Prevention.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Lina Ya'QoubDivision of Structural Heart Disease, University of California (San Francisco), San Francisco, CA 93106, USA.
Jelena ArnautovicDivision of Interventional Cardiology, Henry Ford Macomb Hospital, Clinton Twp, MI 48038, USA.
Musa SharkawiDivision of Structural Heart Disease, Medical College of Georgia, Augusta, GA 30912, USA.
Mirvat AlAasnagDepartment of Cardiology, King Fahd Medical Center, Jeddah 21589, Saudi Arabia.
Hani JneidDepartment of Cardiology, Saint Luke's Baylor Medical Center, Houston, TX 77030, USA.
Islam Y ElgendyDivision of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40506, USA.ORCID 0000-0001-9853-7591
Augusta University · USHenry Ford Macomb Hospital · USKing Fahad Hospital Jeddah · SAUniversity of California, San Francisco · USUniversity of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere have been significant changes in the optimal antithrombotic regimen post transcatheter aortic valve implantation (TAVI) after the results of major clinical trials in the past few years. Given the clinical importance of the optimal antithrombotic therapy post TAVI, we performed a narrative description of the major clinical trials behind the scientific evidence supporting these changes, as well the current guideline recommendations and knowledge gaps.

methodsWe performed a narrative description of the major clinical trials behind the scientific evidence supporting these changes. We used PubMed as a major source to collect the major clinical trials including the following key words: "transcatheter aortic valve replacement", "transcatheter aortic valve implantation", "antithrombotic", "antiplatelet" and "anticoagulation". We selected the major clinical trials on this topic. This is not a systematic review or meta-analysis.

resultsWe describe the results of the major clinical trials on antithrombotic therapy post TAVI: POPULAR-TAVI A, POPULAR-TAVI B, ENVISAGE-TAVI AF, GALILEO, ATLANTIS and ADAPT-TAVR trials. Based on the results of these trials, single antiplatelet therapy is recommended post TAVI in patients without concomitant indication for oral anticoagulation or dual antiplatelet therapy, especially in elderly patients. In younger patients, it is advised to evaluate the patient's bleeding and thrombotic risk, and dual antiplatelet therapy may be reasonable in patients with a high thrombotic risk and low bleeding risk. In patients with a concurrent indication for oral anticoagulation or dual antiplatelet therapy, it is recommended to continue oral anticoagulation or dual antiplatelet therapy post TAVI.

conclusionIn most patients without concomitant indication for oral anticoagulation, single antiplatelet therapy is recommended post TAVI.

Indexed as

anti-coagulationantiplateletantithromboticstructural heart diseasetranscatheter aortic valve implantation

Identifiers

PMID38137701
PMCPMC10743716
OpenAlexW4389624638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.